Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Affitech AS


Contact Details:
Gaustadalleen 21
Oslo
N-0349
Norway
Tel:+47 22 95 88 77
Fax:+47 22 95 83 58
Email:d.stromme@affitech.com
WWW:

www.affitech.com/




Recent Publications by Affitech AS:

High-level periplasmic expression and purification of scFvs.
The isolation of recombinant antibodies by phage display naturally leads...
21st October, 2009
Affitech AS, Oslo Research Park, Gaustadalleen 21, N-0349, Oslo, Norway. Methods Mol Biol. 2009;562:205-14.
DOI Direct Link
Generation of bispecific and tandem diabodies.
Conventionally, antibody phage display has been used to isolate...
21st October, 2009
Affitech AS, Oslo Research Park, Gaustadalleen 21, N-0349, Oslo, Norway. Methods Mol Biol. 2009;562:177-93.
DOI Direct Link
Screening human antibody libraries against carcinoma cells by affinity purification and polymerase chain reaction.
Bacterial scFv clones from a naive antibody library have been isolated...
5th April, 2008
Affitech AS, Oslo Research Park, Gaustadalleen 21, Oslo, Norway. J Immunol Methods. 2008 Jan 31;330(1-2):44-56. Epub 2007 Nov 29.
DOI Direct Link
Construction, evaluation and refinement of a large human antibody phage library based on the IgD and IgM variable gene repertoire.
The ability to isolate antibodies against any antigen of interest has...
23rd July, 2005
Affitech AS, Oslo Research Park, Gaustadalleen 21, 0349 Oslo, Norway. J Immunol Methods. 2005 Apr;299(1-2):47-62. Epub 2005 Mar 8.
DOI Direct Link
Covalent antibody display--an in vitro antibody-DNA library selection system.
The endonuclease P2A initiates the DNA replication of the bacteriophage P2...
11th February, 2005
Affitech AS, Oslo Research Park Gaustadalleen 21, N-0349 OSLO, Norway. Nucleic Acids Res. 2005 Jan 14;33(1):e10.
DOI Direct Link

View more Affitech AS research publications.

Press Releases on Affitech AS:

BioPortfolio Logo
Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies 28th April, 2009 Affitech AS
OSLO, Norway, April 28 /PRNewswire/ -- Affitech AS, the human antibody therapeutics company, announced today that preclinical data on two fully human anti-PS (phosphatidylserine) antibodies were
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 22nd April, 2009 Peregrine Pharmaceuticals, Inc.
-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform- -Treatment with Mouse Equivalent to
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 21st April, 2009 Peregrine Pharmaceuticals, Inc.
- Preclinical Studies Highlight the Ability of PS-Targeting Antibodies to Reverse the Immune Suppressing Effects of Tumors by Changing the Tumor Microenvironment and Mobilizing Key Components of the
Affitech Strengthens Patent Position on its Phagemid Antibody Screening Technology in Europe 2nd April, 2009 Affitech AS
OSLO, Norway, April 2 /PRNewswire/ -- The human antibody company, Affitech AS announced today that the European Patent Office has granted an European patent on the use of phagemid particles having an
Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company 4th March, 2009 Affitech AS
COPENHAGEN and OSLO, March 4 /PRNewswire/ -- Pharmexa A/S and Affitech AS announced today that they have entered into a conditional agreement to merge the two companies by means of a share for

BioNews Results for Affitech AS:

Affitech Announces New Scientific Findings for its r84 Fully Human VEGF/VEGFR2 Selective Antibody
EuroInvestor.co.uk:  Nov 6 2009 5:52PM Matching: affitech
Affitech Announces New Scientific Findings for its r84 Fully Human VEGF/VEGFR2 Selective Antibody
Therapeutics Daily:  Nov 6 2009 12:19PM Matching: affitech
R&D Pipeline News. Volume 5, Issue 39: Her2 Receptor Antagonists
PipelineReview:  Oct 13 2009 12:28AM Matching: affitech
Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development
Pharma Live:  Sep 1 2009 1:34PM Matching: affitech
Affitech Appoints Dr Robert Burns as CEO and Dr Alexander Duncan as SVP Research & Development
PR Newswire via Yahoo!:  Sep 1 2009 12:51PM Matching: affitech
Promote your company here: BioNewsCast - Press Release Distribution

View more Affitech AS news.

Affitech AS Patents:

US Patent No.Title
6884629 Immunoglobulin binding protein
6822075 Protein L and hybrid proteins thereof
6380365 Temperature dependent ligand facilitated purification of proteins

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 1008 times since April 2007, the link to the organisation's website has been followed 161 times

Recent Search Terms used to find this page: Dr Robert Burns Affitech contact email address | Gaustadalleen 21 N-0349 OSLO Norway | Affitech AS | Affitech antibody | Affitech | affitech phage p2 | affitech | affitech | Affitech AS oslo | Methods Mol Biol. 2009 562 177-93 | .

Search for more companies in Oslo

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Affitech AS

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.